Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will Pharmasset’s $11 Billion Windfall Benefit Other HCV Players?

Dec 27 2011

Related Content

Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo

Nov 14 2011

Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

Nov 21 2011

Related Companies

Gilead Sciences, Inc.

Pharmasset, Inc.

Inhibitex, Inc.

Idenix Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc.

Amgen, Inc.

Merck & Co., Inc.

Roche Holding AG

Bristol Myers Squibb Company

Additional Topics

Europe United States Business Strategies Deals BioPharmaceutical

More from Global Vision

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window